Escape from apoptosis is a common hall mark of viral infection that contributes to viral replication and propagation. Apop tosis proceeds via a caspaseactivation cascade that is triggered either extrinsically (death receptormediated) or intrinsically (mitochondriadependent), which results in the collapse of cellular infrastructure, mitochondrial membrane potential and cell membrane integrity (reviewed in REF. 1 ). To evade elimination via apoptosis, viruses, including many oncogenic viruses, target key regulatory steps in the apoptotic path way 2 , including the inhibition of death receptormediated apoptotic signalling, as has been shown for viral FLICElike inhibi tory protein (vFLIP; also known as caspase 8inhibitory protein); the modulation of mitochondrial permeability, as exempli fied by viral homologues of the apoptosis regulator B cell lymphoma 2 (BCL2); and interference with caspase activation by viral inhibitor of apoptosis (vIAP). In addition, viruses can inhibit apoptosis by targeting the proapoptotic tumour suppressor p53.
Importantly, a growing body of evidence shows that, in addition to their role in inhibiting apoptosis, these virally encoded proteins function in several immune and metabolic pathways, including autophagy, activation of nuclear factorκB (NFκB), interferon (IFN) signalling and cytoskeleton remodelling. As loss of homeostatic balance and immune activation promote the pro gression of viral infection and underlie path ogenic mechanisms in many virusinduced pathologies, a comprehensive understanding of these novel properties of viral apoptotic inhibitors could aid in the development of new strategies to prevent and treat multiple viral infectious diseases. In this Progress article, we discuss recent studies that have provided insights into novel functions of viral antiapoptotic factors in the regulation of autophagy, in the NFκB pathway and in IFN signalling. We mainly focus on onco genic gammaherpesviruses
, especially the human pathogen Kaposi's sarcoma associated herpesvirus (KSHV) and a close relative of KSHV, mouse gammaherpesvirus 68 (γHV68), as the molecular or physi ological functions of their antiapoptotic factors have been most extensively studied and are likely to be conserved among other persisten t viruses.
Modulation of autophagy
Initially discovered as a cellular response to nutrient deficiency, macroautophagy (hereafter referred to as autophagy) has since been proven to be a fundamental homeo static process in every eukaryotic organism 3 . In contrast to the apoptotic ('selfkilling') programme, autophagy ('selfeating') involves lysosomedependent bulk degrada tion of cytoplasmic proteins and organelles in a characteristic doublemembranecoated vesicle, known as the autophagosome 3 . The process of autophagy includes induction, nucleation of the phagophore, elongation, fusion and degradation. As part of its intrinsic role in maintaining homeostasis, autophagy is a cellular defence mechanism against infections by various pathogens (for more details, see REF. 4 ). The cytoplasmic localization of autophagosomes enables them to target intracellular pathogens or pathogen components for lysosomal degra dation. In addition, autophagic degradation releases signals for viral recognition, type I IFN secretion, as well as antigen presenta tion 4 . Hence, autophagy is important in anti viral immunity and is therefore blocked by certain viruses to establish successful infec tion 5 . This is particularly pertinent in KSHV, which establishes longterm latent infection in lymphoid or endothelial cells, in which it can be reactivated, sometimes frequently, to cause recurrent disease and viral spreading, without being cleared by the host immune system 6 . Almost every stage of the autophagy pathway is targeted by KSHV proteins that were originally identified as inhibitors of apoptosis. Such a dual role in both apopto sis and autophagy reflects the substantial crosstalk between the host apoptotic and autophagic machineries during viral infec tion. For clarity, we discuss the many inter actions between viral antiapoptotic factors and the host autophagy pathway in relation to the linear cascade of the autophagic progress (FIG. 1) .
Targeting induction. Gammaherpesviruses interfere with upstream autophagy signal ling by targeting the 'nutrient sensor' , mammalian target of rapamycin complex 1 (mTORC1), which integrates metabolic sig nals from the microenvironment of the cell and represses the autophagyinitiating ULK1 complex [7] [8] [9] (FIG. 1) . Viral proteins, including K1, viral interleukin6 (vIL6) and a viral G proteincoupled receptor (vGPCR) of KSHV, have been shown to promote the activation of the phosphoinositide 3kinase (PI3K)-AKT-mTORC1 pathway, which is required for the development of the KSHVassociated Abstract | Cellular apoptosis is of major importance in the struggle between virus and host. Although many viruses use various strategies to control the cell death machinery by encoding anti-apoptotic virulence factors, it is now becoming clear that, in addition to their role in inhibiting apoptosis, these factors function in multiple immune and metabolic pathways to promote fitness and pathogenesis. In this Progress article, we discuss novel functions of viral anti-apoptotic factors in the regulation of autophagy, in the nuclear factor-κB (NF-κB) pathway and in interferon signalling, with a focus on persistent and oncogenic gammaherpesviruses. If viral anti-apoptotic proteins are to be properly exploited as targets for antiviral drugs, their diverse and complex roles should be considered. vascular tumour Kaposi's sarcoma 7, 8 . More recent findings further established that the activation of the ERK2-RSK1-TSC2 pathway by the KSHV protein ORF45 also contributes to activation of mTORC1; however, surprisingly, this only occurred in lymphatic endothelial cells and not in blood vessel endothelial cells 10 , which suggests that there is a tissuespecific pathogenic mecha nism. It remains to be determined whether inhibition of autophagy is involved in KSHVassociate d sarcomagenesis; however, constitutive stimulation of mTORC1 signal ling may be an important viral mechanism to suppress autophagy in infected cells and promote longterm survival of the virus and oncogenic transformation.
Targeting nucleation. Nucleation of the phagophore is driven by the activation of the Beclin1associated class III PI3K (PI3KC3) complex 3 (FIG. 1) . This process is suppressed by the antiapoptotic protein BCL2, which binds to Beclin1 to prevent autophagosome formation 11 . Virusencoded orthologues of BCL2 (vBCL2) contribute to immune evasion in all gammaherpes viruses, including Epstein-Barr virus (EBV), KSHV, herpesvirus saimiri and γHV68. Initial studies on vBCL2 focused on its ability to prevent the mitochondrial release of apoptogenic factors, which enables completion of viral replication 12 . Paradoxi cally, loss of vBCL2 in γHV68 and KSHV did not affect acute infection but instead severely impaired chronic infection in the host 13, 14 , which suggests that its inhibitory effect on apoptosis is not the sole action of vBCL2 and that other targets are also involved in vBCL2mediate d virulence. It is now clear that, analogous to the cellular counterpart, the vBCL2 proteins of KSHV and γHV68 attenuate autophagy via direct interaction with host Beclin1 and confer even more robust inhibition than the host BCL2 (REF. 15 ). In addition, the affinity of vBCL2 proteins for Beclin1 is higher than that of proapoptotic BCL2 family mem bers such as BAX or BAK, which suggests that Beclin1 is the main target of vBCL2 proteins of KSHV and γHV68 during chronic infection 15 . Consistent with this, targeted elimination of the antiautophagic activity of vBCL2 severely attenuated the ability of γHV68 to maintain a latent reser voir in splenocytes, which is a prerequisite for persistent infection and transmission, whereas the mutant virus that lacks the anti apoptotic property of vBCL2 had reduced viral reactivation frequency 16 . These findings suggest that vBCL2mediated inhibition of autophagy and evasion of apoptosis have different roles in the γHV68 life cyclemaintenanc e of the latent reservoir and reactivation, respectively 16 . As persistent infection is crucial for gammaherpesvirus associated malignancy, vBCL2mediated inhibition of autophagy might contribute to the oncogenic potential of these viruses 13 . It is not currently clear whether the two viral BCL2 homologues (BHRF1 and BALF1) that are encoded by EBV also have the capa bility to inhibit autophagy; however, owing to their structural and functional homology to cellular BCL2, it seems likely that BHRF1 and/or BALF1 may also function as anti autophagic factors. Importantly, Beclin1 mediated autophagy is also targeted by other antiapoptoti c proteins from other herpesvi ruses; for example, the neurovirulence factor, ICP34.5, which prevents apoptosis in herpes simplex virus 1 (HSV1)infected cells, directly binds to Beclin1 and thereby blocks virusinduced autophagy 17 . Notably, the control of autophagy by vBCL2 is both complex and context specific, as the interaction of the adenoviral BCL2 homologue E1B19K with Beclin1 results in the induction of autophagy, which might be required for lytic replication 18 .
Inhibiting autophagosome elongation. In addition to targeting autophagy induction and nucleation, gammaherpesviruses have evolved a second strategy to subvert this host process by expressing latencyassociated vFLIP. This viral protein contains two death effector domains and was originally described to inhibit death receptormediated caspase activation 19 . However, recent data suggest that vFLIP from KSHV can induce the NFκB pathway (see below) and impair elongation of the autophagosome membrane in latently infected cells 19, 20 . Autophagosome elonga tion involves two ubiquitinlike conjugation reactions, one in which ATG12 is covalently attached to ATG5 and one in which LC3 (mammalian ATG8) is covalently attached to phosphatidylethanolamine (reviewed in REF.
3) (FIG. 1) . Conjugation of LC3 to autophagosomebound phosphatidyletha nolamine is sequentially processed by ATG7 (an E1like enzyme) and ATG3 (an E2like enzyme) 3 . A study showed that both KSHV vFLIP and cellular FLIP (cFLIP) compete with LC3 for binding to ATG3, but vFLIP has evolved to be a more potent inhibitor of autophagosome expansion than cFLIP 20 . In support of this finding, expression of vFLIP inhibits rapamycininduced autophagic cell death of KSHVinfected B lymphocytes 20 . Despite these advances in our understand ing of the role of vFLIP in the regulation of autophagy, the exact function of vFLIP mediated inhibition of autophagy during viral infection remains unclear. It was speculated that the antagonism of host autophagy by vFLIP may promote chronic infection. It is also worth noting that persistent suppression of autophagy could have important noncyto lytic oncogenic roles; for example, it may be involved in antagonizing autophagyrelated antigen presentation of viral latent proteins to escape immune detection. Strikingly, a peptide derived from KSHV vFLIP has the opposite effect by binding to vFLIP itself and thereby preventing the vFLIP-ATG3 interac tion, which leads to a substantial induction of autophagyrelated death of KSHVinfected cells 20 . The potent effects and functional specificity of the gammaherpesvirusderived antiviral peptides might be useful in the treatment or prevention of infection.
Box 1 | Oncogenic gammaherpesviruses
The gamma subfamily of herpesviruses comprises two major genera: the lymphocryptoviruses (also known as gamma-1), which include human Epstein-Barr virus; and rhadinoviruses (also known as gamma-2), which include human Kaposi's sarcoma-associated herpesvirus (KSHV). A striking feature that is shared by members of the gammaherpesvirus family is their ability to establish life-long latency in their hosts, with intermittent periods of lytic replication, which are associated with the development of several types of malignancies, including B cell lymphomas 6 . Viral proteins that are expressed during both the latent and lytic phases contribute considerably, albeit differently, to gammaherpesvirus-associated oncogenesis. Evasion of host immune responses that would otherwise eliminate the virus is crucial to the ability of the virus to maintain persistent infection. Via co-evolution with their host, gammaherpesviruses have evolved elaborate strategies to subvert the host defence mechanisms; for example, almost 50% of the KSHV genome is dedicated to modulating the host immune response, including blockage of innate apoptotic effects 6 . Intriguingly, most of these viral immune modulators, such as B cell lymphoma 2 (vBCL-2), viral FLICE-like inhibitory protein (vFLIP), viral inhibitor of apoptosis (vIAP) and viral interferon regulatory factor (vIRF), seem to be 'pirated' from the host and expressed as native host proteins or as homologues of host proteins to avoid being targeted by a particular branch of the immune system. These evasion strategies contribute substantially to the incidence of viral malignancies and their resistance to immune control.
Modulating autophagosome maturation.
Mammalian viruses express structural homologues of IAP, which, similarly to cel lular IAP, have antiapoptotic function; for example, KSHV vIAP, which is encoded by the ORF K7 and localizes to mitochondria in infected cells, has been shown to inhibit apoptosis in response to several stimuli 21 . In addition to the diverse antiapoptotic roles of vIAP, a distinct function for this viral protein in the late stage of autophago some maturation was recently identified 22 , and this has not been found in its cellular counterpart. The autophagosome matures by fusion with the late endosome and the lysosome, which is a process that is nega tively regulated by Rubicon (RUN domain Beclin1interacting and cysteinerich con taining protein) in complex with UVRAG (UV irradiation resistanceassociated protein), Beclin1 and other members of the PI3KC3 complex 23 (FIG. 1) . Overexpression of Rubicon results in the accumulation of autophagic cargoes, whereas Rubicon deple tion induces their degradation, consistent with a role in the inhibition of autophagy 23 . KSHV vIAP interacts with Rubicon and increases its inhibitory effect on autophago some maturation in lytically infected cells 22 . Although the in vivo relevance of vIAP mediated inhibition of autophagic degrada tion has not been investigated, it is likely that it may promote survival of the virus in host cells.
In summary, the involvement of different viral antiapoptotic proteins in various steps of autophagy suggests that interference with this cellular process is a common strategy that is used by viral pathogens and could therefore be a potential therapeutic target for the treatment of virally associated malignancies in gammaherpesvirus infection.
Regulating NF-κB signalling
The NFκB pathway is a prime target for viral pathogens as many of the protein products of NFκB target genes profoundly influence the host cell microenvironment and the immune response 24 . Whereas tran sient activation of NFκB is an integral part of normal physiological regulation, excessive and persistent activation of NFκB signalling is often promoted by tumorigenic viruses to optimize their intracellular stage and to induce chronic inflammation and oncogenic transformation 25 . In addition, some viruses modulate the NFκB pathway to either evade host apoptosis to increase the production of progeny virions, or conversely, to trigger cell lysis to increase viral spread. Thus, the context of NFκB signalling is an important consideration; the same virulence factor may have opposite effects depending on when and where it is deployed. Nature Reviews | Microbiology Autophagy proceeds through a series of steps, which include induction, phagophore nucleation, elongation and fusion of the autophagosome with the lysosome for degradation of the sequestered cargoes. Mammalian target of rapa mycin complex 1 (mTORC1) is a negative regulator of autophagy that, under nutrient-rich conditions, prevents the assembly and the activation of the autophagy-initiating ULK complex (which comprises ULK1, ATG13 and FIP200) (step 1). mTORC1 is inactivated in response to various stimuli (for example, starvation) and autophagy is induced. Viral G protein-coupled receptor (vGPCR), K1 and viral interleukin-6 (vIL-6) of Kaposi's sarcoma-associated herpesvirus (KSHV) promote the constitutive activation of mTORC1, which may suppress autophagy in infected cells. Phagophore nucleation is driven by the class III phosphoinositol 3-kinase complex (PI3KC3), which includes Beclin1 (step 2). The activity of this lipid kinase complex is inhibited by the anti-apoptotic viral B cell lymphoma 2 (vBCL-2) of gammaherpesviruses, which strongly sequesters Beclin1 to suppress phagophore nucleation. Growth and closure of the autophagosome membrane involve the conjugation of the autophagy marker LC3 to phospha tidylethanolamine in the membrane, which is sequentially processed by ATG4, ATG7 and ATG3 (step 3). KSHV FLICE-like inhibitory protein (vFLIP) competes with LC3 for binding to ATG3 to inhibit expansion of the autophagosome. The fusion of the autophagosome with the lysosome to form a single membrane-bound autolysosome signifies the maturation stage of the autophagy pathway (step 4). Consequently, the encapsulated contents, together with the inner membrane of the autophagosome, undergo breakdown by lysosomal hydrolases. Maturation is negatively regulated by the host Rubicon complex, which comprises Rubicon, UVRAG (UV irradiation resistance-associated protein), Beclin1 and other members of the PI3KC3 complex. KSHV viral inhibitor of apoptosis (vIAP) forms a complex with Rubicon and enhances Rubiconmediated inhibition of autophagosome maturation.
Members of the mammalian NFκB family of transcription factors form hetero dimers and activate or inhibit the expres sion of several genes, including the genes that encode proinflammatory cytokines, chemokines and their respective receptors, as well as genes that regulate cell survival and proliferation. In most cell types, NFκB complexes are sequestered in the cytoplasm by a family of inhibitory proteins known as inhibitors of NFκB (IκBs). A remarkably diverse range of stimuli and viral factors, including Tax from human T cell leukaemia virus type 1 (HTLV1), Tat from HIV1, LMP1 from EBV, UL31 from HSV1, UL144 from human cytomegalovirus (HCMV) and HBx from hepatitis B virus (reviewed in REF. 25 ), function via distinct mechanisms to activate NFκB, but most of these mecha nisms converge on the upstream IκB kinase (IKK) complex 24 . The IKK complex consists of two catalytic subunits, IKKα and IKKβ, and the noncatalytic scaffold and regulatory subunit, NFκB essential modifier (NEMO), and is activated by cytosolic adaptors (for example, the TRAF family of proteins) 24 . IKKmediated phosphorylation subsequently targets IκB for protein degradation, which enables NFκB to translocate to the nucleus and regulate target gene expression. Together with IKKα and IKKβ, NEMO functions as a molecular switch to activate the canonical NFκB pathway, which has been shown to be modulated by KSHV vFLIP to promote viral latency and pathogenesis.
vFLIP targets NF-κB signalling. As men tioned in the previous sections, the impor tance of vFLIP for viral infection has only recently been understood, concomitant with an appreciation for the crucial role of NFκB activation and the regulation of autophagy in chronic gammaherpesvirus infection and pathogenesis 19, 26, 27 . Although vFLIP was ini tally shown to inhibit caspase activation and Fasmediated apoptosis 28 , this finding was not confirmed in vFLIPexpressing trans genic mice 19 . Instead, vFLIP expression was found to induce NFκBregulated cytokine expression and secretion and to contribute to the proinflammatory microenvironment of Kaposi's sarcoma 29 . In addition to the secre tion of cytokines, the constitutive activation of NFκB signalling by vFLIP is mecha nistically associated with the spindle cell morphological transformation of endothelial cells, which is a hallmark of Kaposi's sarcoma lesions 30 . Of note, deregulated activation of NFκB by vFLIP also induces the transcrip tional activation of several host antiapoptotic factors, such as BCL2 and BCLX L , cIAP1 and cIAP2, which promotes the resistance of virally infected cells to programmed cell death 31, 32 . In accordance with this, RNA interference (RNAi)mediated silencing of vFLIP or treatment with specific NFκB inhibitors triggered apoptosis of KSHV transformed B cells and impaired tumori genesis in mice with KSHVtransformed cells 33, 34 . Thus, it is conceivable that vFLIP blocks host apoptosis either directly via caspase inactivation or indirectly via the activation of NFκBdependent transcrip tion factors that induce antiapoptotic target genes, which is essential for the survival and transformation of infected cells.
Unlike cFLIP, which is cleaved by active caspase 8 and then interacts with TRAF or NEMO to activate NFκB 35 , KSHV vFLIP stimulated NFκB signalling bypasses the upstream mediators (such as TRAF family proteins) and directly binds to NEMO to assemble the vFLIPresponsive IKK signalo some, which leads to the continuous activa tion of NFκB [36] [37] [38] (FIG. 2a) . In agreement with this, a recent observation 39 indicates that binding of KSHV vFLIP to NEMO induces a conformational shift in NEMO from a helical bundle to an open conforma tion, which activates the catalytic subunits of IKKα and IKKβ. Indeed, KSHV vFLIP can induce both the canonical and non canonical NFκB pathway via an upstream adaptorindependent and NEMO and IKKαdependent mechanism. In addition, the crosstalk of other parallel signalling pathways may affect the vFLIPmediated NFκB response during different stages of the viral life cycle. A recent study 40 showed that vFLIP also inhibits NFκB: expres sion of vFLIP was found to induce robust phosphorylation of NEMO at Y374 and S377, which normally confers a negative feedback loop for tumour necrosis factor (TNF)induced NFκB activation. Fur thermore, A20 binds to vFLIP and blocks vFLIPinduced activation of NFκB, which generates a negative feedback loop to regu late vFLIPmediated NFκB signalling 41 . Although it remains unclear whether the antiinflammatory roles of vFLIP result from a viralspecific process or from the secondary effects of host defences, the abil ity of vFLIP to induce -as well as to repress -NFκB suggests that activation of NFκB is not always the default pathway for host immunity during viral infection. Strate gies to modulate, rather than to induce or inhibit, NFκB could promote a beneficial outcome for the virus, which should also be considered for the therapeutic targeting of the NFκB pathway.
Interference with the IFN response Although apoptosis is a formidable defence mechanism against viral infection, it is also costly to the host. This is particularly true for irreplaceable cells such as neurons. 43 . In addition to inhibiting apoptosis dur ing in vivo infection, vIRFs are equally -if not more -crucial for the dysregulation of virusmediated induction of IFNs for a sustained infection and for immune evasion (FIG. 2b) . KSHV vIRF1, vIRF2 and vIRF3, but not vIRF4, have all been shown to inhibit the induction of IFN and IFNstimulated genes (ISGs) in infected cells via interference with IRFs 43 . Unlike vIRF1 and vIRF2, which mainly target the IRF3mediated IFN and inflammatory response, vIRF3 interacts with IRF7 and inhibits its DNAbinding activity, thereby abrogating the production of IFNα 43 . A recent study 44 showed that vIRF4 functions as a dominant inhibitor of cellular IRF4, but instead of decreasing IFN signalling, vIRF4 inhibits IRF4dependent expression of the cMYC protooncogene, which is probably needed for productive viral reactivation. Although different vIRFs often target the same cellular pathways, they may function differently depending on the cellular con text and the stage of the viral life cycle to promote viral replication and oncogenicity. Collectively, the involvement of vIRFs in both IFN and apoptosismediated antiviral defence suggests that these two processes are tightly linked and are regulated in a coordi nated manner, which makes vIRFs promising therapeutic targets for viral infection control.
Conclusions
Disruption of cellular apoptosis is a com mon strategy of viruses. The apoptosis pathway in host cells does not exist in isola tion and is integrated with other cell signal ling networks. This crosstalk reshapes the biological functions of viral antiapoptotic factors during virus-host coevolution. As outlined in this Progress article, viral anti apoptotic factors have evolved to exploit multiple metabolic and immune pathways, including, but not limited to, autophagy and Following stimulation by extracellular stress signals or viral pathogens, the IKK complex is activated and phosphorylates IκBs, which leads to their proteosomal degradation and the release of NF-κB dimers. Binding of KSHV vFLIP to NEMO induces and stabilizes a conformational change in the host protein that enables the recruitment of IKKα and IKKβ and the continuous activation of NF-κB. NF-κB induces the expression of inflammatory, proliferative and antiapoptosis genes, including the gene that encodes A20. A20 binds to vFLIP and blocks vFLIP-induced NF-κB activation, which generates a negative feedback loop. In addition, expression of vFLIP enhances the phophorylation of NEMO at Y374 and S377, which negatively regulates its function. The dual regulation of NF-κB signalling by vFLIP suggests that the virus modulates this pathway to promote survival. b | KSHV encodes a cluster of four viral homologues of interferon (IFN) regulatory factors (IRFs) (vIRF1-4). In addition to suppressing p53-mediated apoptosis, vIRFs also function as negative regulators of type I IFN responses. Transcription of type I IFNα and IFNβ following viral infection is primarily controlled by IRF3 and IRF7. Cytoplasmic IRF3 and IRF7 undergo phosphorylation, homodimerization and heterodimerization, followed by nuclear translocation to induce the expression of type I IFNs. Binding of IFNs to the type I IFN receptor (IFNR) induces the expression of IFN-stimulated genes (ISGs), which initiate an intracellular antiviral programme to restrict viral replication and spread. Both vIRF1 and vIRF2 inhibit IRF3-mediated transcriptional activation and the production of IFNβ, whereas vIRF2 can also inhibit IFNα-induced induction of IFN-stimulated response element (ISRE)-containing genes. vIRF3 specifically interacts with, and inhibits, IRF7 and thereby abrogates the production of IFNα and IFN-mediated immunity. vIRF4 is an inhibitor of IRF4, which unlike other vIRFs, mainly inhibits IRF4-mediated expression of the proto-oncogene c-MYC to facilitate viral lytic replication and/or reactivation. ISGF3, IFN-stimulated gene factor 3; JAK, Janus kinase; TYK2, non-receptor tyrosine kinase 2. Nature Reviews | Microbiology the IFN and NFκB signalling pathways, by directly interacting with key factors of these host pathways. Intriguingly, their diverse roles are often independent of their antiapoptotic properties; for example, a recent study has shown that, in addition to blocking apoptosis at the mitochondrial checkpoint, the HCMV homologues of mitochondrial inhibitor of apoptosis (vMIA) can coopt the host antiviral protein Viperin to disrupt the cytoskeleton, which in turn promotes replication of the virus 45 . However, how these new immunemodulatory func tions of virulence factors are finetuned in host-pathoge n interactions and how they relate to the regulation of the viral life cycle and pathogenesis, as well as how they relate to host pathological conditions, remain unknown. Therefore, an understanding of the complexity and specificity of the viral strategy to subvert apoptosis and how this is integrated with other signalling networks has the potential to inform appropriate therapeutic strategies and provides an opportunity for the effective exploitation of these proteins in the treatment of different infectious diseases in the future.
